Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.

[1]  D. J. Price,et al.  Imidazo[1,2-a]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization. , 2012, ACS medicinal chemistry letters.

[2]  C. Trautwein,et al.  Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. , 2012, Journal of hepatology.

[3]  I. Jacobson,et al.  Advances in the treatment of hepatitis C virus infection. , 2012, Gastroenterology & hepatology.

[4]  Lingling Jia,et al.  Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052 , 2012, Antimicrobial Agents and Chemotherapy.

[5]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[6]  J. Deval,et al.  New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. , 2011, Antiviral research.

[7]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[8]  J. Glenn,et al.  The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. , 2010, The Journal of infectious diseases.

[9]  Darius Moradpour,et al.  Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory , 2010, Reviews in medical virology.

[10]  P. A. Thompson,et al.  Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase. , 2009, Bioorganic & medicinal chemistry letters.

[11]  T. Berg,et al.  Expert opinion on the treatment of patients with chronic hepatitis C , 2009, Journal of viral hepatitis.

[12]  P. Almasio,et al.  New therapeutic prospects in HCV treatment , 2008, Expert review of anti-infective therapy.

[13]  A. F. Jensen,et al.  New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells. , 2006, Journal of medicinal chemistry.

[14]  M. Fray,et al.  A Practical Synthesis of 3,3‐Difluorocyclobutane Carboxylic Acid , 2005 .

[15]  Nan Zhang,et al.  Facile synthesis of 1,1-gem-dialkylperfluoroalkylamines , 2002 .

[16]  J. McHutchison,et al.  New therapeutic strategies for hepatitis C , 2002, Hepatology.

[17]  D. Gretch,et al.  Hepatitis C virus: current understanding and prospects for future therapies. , 1999, Molecular medicine today.

[18]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[19]  J. Silver,et al.  Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line , 1999 .

[20]  J Cohen,et al.  The Scientific Challenge of Hepatitis C , 1999, Science.

[21]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[22]  V. Soloshonok,et al.  Highly Enantioselective Transfer of Chirality from a Less to a More Configurationally Unstable Stereogenic Center. A Practical Asymmetric Synthesis of (Fluoroalkyl)amines via Biomimetic Transamination. , 1997, The Journal of organic chemistry.